Clinical trials: Multiple Myeloma, Refractory
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Multiple Myeloma
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed.
- Trial name
- TEC-CARE (NCT06062537)
- Where
- 31 sites in France
- Volunteers
- 200 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
- Trial name
- NCT00352742
- Testing
- ATN-224 + bortezomib
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenuon
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003270
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03829020
- Testing
- Bortezomib, Metformin Hydrochloride, Nelfinavir Mesylate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden to enable renal recovery, which is correlated with prognosis of the patients.
- Trial name
- GMMG-DANTE (NCT02977494)
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 10 sites in Germany, Greece
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma
This pilot clinical trial studies how well simvastatin works in overcoming chemotherapy resistance in patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT02971410
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Simvastatin
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
The purpose of this study is to evaluate the multi-lineage hematopoietic chimerism for unrelated umbilical cord blood (UCB) grafts pooled from two to three cord blood units.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01500161
- Testing
- Busulfan, Clofarabine, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Texas Oncology Cancer Center
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of selvigaltin when given together with standard of care treatment (daratumumab-hyaluronidase, carfilzomib, dexamethasone) in treating patients with multiple myeloma that…
- Trial name
- NCT07082270
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Relapsed or Refractory Multiple Myeloma
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
- Trial name
- NCT03815383
- Testing
- C-CAR088
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anxiety Disorder, Chronic Myeloproliferative Disorders
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
RATIONALE: Music therapy may be effective in relieving pain and emotional distress in patients who are undergoing cancer therapy.
- Conditions
- Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma
- Trial name
- NCT00014482
- Testing
- pain therapy, psychosocial assessment and care
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04156269
- Testing
- BCMA-CS1 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Multiple Myeloma
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen…
- Trial name
- NCT01365559
- Testing
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma, Recurrent Multiple Myeloma
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma.
- Conditions
- Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT05288062
- Testing
- Bone Marrow Biopsy, Dexamethasone, Lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
- Trial name
- NCT03340883
- Testing
- BION-1301
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Chinook Therapeutics, Inc.
Relapsed/Refractory Multiple Myeloma
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, two-cohort, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with…
- Trial name
- NCT06472479
- Testing
- LCAR-M61S cells preparation, LCAR-M61D cells preparation
- Where
- 4 sites in China
- Volunteers
- 66 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center